2025
Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium.
Trongtorsak A, De La Rosa Martinez J, Crawford T, Bogun F, Gu X, Purroll E, Ellenbogen K, Chicos A, Roukoz H, Zimetbaum P, Kalbfleisch S, Murgatroyd F, Steckman D, Rosenfeld L, Soejima K, Bhan A, Vedantham V, Dickfeld T, De Lurgio D, Platonov P, Zipse M, Nishiuchi S, Ortman M, Narasimhan C, Patton K, Rosenthal D, Mukerji S, Hoogendoorn J, Zeppenfeld K, Torosoff M, Judson M, Martin K, Madias C, Hermel M, Nour K, Torbey E, Sauer W, Kron J. Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium. Circulation Arrhythmia And Electrophysiology 2025, e013670. PMID: 40557494, DOI: 10.1161/circep.124.013670.Peer-Reviewed Original ResearchLeft ventricular ejection fractionCardiac sarcoidosisVentricular ejection fractionBlack patientsEjection fractionNo significant differenceClinical outcomesPrimary outcomeWhite patientsImplantable cardioverter defibrillator therapyLeft ventricular assist device implantationSignificant differenceVentricular assist device implantationComposite end pointChronic kidney diseaseChronic obstructive pulmonary diseaseAll-cause mortalityAssist device implantationRates of lungRates of hypertensionObstructive pulmonary diseaseImplantable cardioverter defibrillatorExtracardiac involvementEye involvementHeart transplantationComparative Safety and Efficacy of Balloon Mounted Stents and Self Expanding Stents in Rescue Stenting for Large Vessel Occlusion: Secondary analysis of the RESCUE-ICAS Registry.
Al Kasab S, Mierzwa A, Tahhan I, Yaghi S, Jumaa M, Inoa V, Capasso F, Nahhas M, Starke R, Fragata I, Bender M, Moldovan K, Maier I, Grossberg J, Jabbour P, Psychogios M, Samaniego E, Burkhardt J, Altschul D, Mascitelli J, Ezzeldin M, Grandhi R, de Havenon A, Nguyen T, Hassan A. Comparative Safety and Efficacy of Balloon Mounted Stents and Self Expanding Stents in Rescue Stenting for Large Vessel Occlusion: Secondary analysis of the RESCUE-ICAS Registry. American Journal Of Neuroradiology 2025, ajnr.a8895. PMID: 40550702, DOI: 10.3174/ajnr.a8895.Peer-Reviewed Original ResearchBalloon-mounted stentsModified Rankin ScaleSelf-expanding stentsLarge vessel occlusionVessel occlusionMechanical thrombectomyRescue stentingClinical outcomesRecurrent strokeInfarct volumePatients treated with mechanical thrombectomyModified Rankin scale 0Symptomatic intracranial hemorrhageMulticenter observational studyInverse probabilityIntracranial atherosclerotic stenosisAssociated with higher oddsRate of restenosisSecondary analysisPrimary endpointIntracranial hemorrhageNo significant differenceFollow-upRankin ScaleIntracranial stenosisSerotonin Norepinephrine Reuptake Inhibitor Is Associated With Lower Mortality Among Patients Presenting With Takotsubo Cardiomyopathy.
Shamaki G, Anuforo A, Safiriyu I, Corteville D, Sanghavi M, Shah S, Clark K. Serotonin Norepinephrine Reuptake Inhibitor Is Associated With Lower Mortality Among Patients Presenting With Takotsubo Cardiomyopathy. Journal Of The American Heart Association 2025, 14: e037951. PMID: 40551298, DOI: 10.1161/jaha.124.037951.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsDiagnosis of takotsubo cardiomyopathyTakotsubo cardiomyopathyPropensity score matchingReuptake inhibitorsClinical outcomes of patientsNorepinephrine reuptake inhibitorsReuptake of serotoninScore matchingOutcomes of patientsOpioid-related disordersCocaine-related disordersAssociated with lower mortalityLower mortalityTriNetX Research NetworkTreatment of depressionAssociated with lowered mortalityAcute myocardial infarctionNeuropathic painPresynaptic reuptakeClinical outcomesCardiac arrestPrimary outcomeSecondary outcomesVentricular fibrillationCognitive bias modification for individuals with opioid use disorder and chronic pain did not predict changes in clinical outcomes.
Wolkowicz N, Pittman B, Schrader S, Wesolowicz D, Sofuoglu M, Heapy A, MacLean R. Cognitive bias modification for individuals with opioid use disorder and chronic pain did not predict changes in clinical outcomes. Journal Of Studies On Alcohol And Drugs 2025 PMID: 40536409, DOI: 10.15288/jsad.25-00057.Peer-Reviewed Original ResearchCognitive bias modificationAttentional biasOpioid cravingBias modificationCBM effectsSubstance use disordersPain severityChronic painClinical outcomesAddiction severityOpioid use disorderUse disorderNaturalistic settingsNeutral-cueOpioid withdrawalPain cuesCravingDiverse sampleSalient outcomesSubstance typePreliminary effectivenessPrimary clinical outcomePain catastrophizingModerate painPain intensityRole of PLK4 inhibition in cancer therapy
Banik K, Hayman T. Role of PLK4 inhibition in cancer therapy. Cancer And Metastasis Reviews 2025, 44: 55. PMID: 40512236, DOI: 10.1007/s10555-025-10271-5.Peer-Reviewed Original ResearchConceptsAssociated with more advanced diseaseCancer therapyAssociated with tumor progressionMore advanced diseasePolo-like kinase 4PLK4 overexpressionMultiple cancer typesAdvanced diseaseTherapeutic resistanceClinical outcomesTumor progressionSmall molecule inhibitorsHuman tumorsCancer typesDNA-damaging agentsSerine-threonine kinaseCancerOncogenic processesTherapeutic gainTherapeutic targetPolo-like kinase 4 inhibitorPLK4 inhibitionKinase 4Genomic instabilityTherapyThe electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
Mathalon D, Nicholas S, Roach B, Billah T, Lavoie S, Whitford T, Hamilton H, Addamo L, Anohkin A, Bekinschtein T, Belger A, Buccilli K, Cahill J, Carrión R, Damiani S, Dzafic I, Ebdrup B, Izyurov I, Jarcho J, Jenni R, Jo A, Kerins S, Lee C, Martin E, Mayol-Troncoso R, Niznikiewicz M, Parvaz M, Pogarell O, Prieto-Montalvo J, Rabin R, Roalf D, Rogers J, Salisbury D, Shaik R, Shankman S, Stevens M, Suen Y, Swann N, Tang X, Thompson J, Tso I, Wenzel J, Zhou J, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Castillo-Passi R, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim M, Kim S, Koutsouleris N, Kwon J, Langbein K, Mamah D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Stone W, Strauss G, Upthegrove R, Verma S, Wang J, Wolf D, Zhang T, Bouix S, Pasternak O, Cho K, Coleman M, Dwyer D, Nunez A, Tamayo Z, Wood S, Kahn R, Kane J, McGorry P, Bearden C, Nelson B, Woods S, Shenton M, Light G. The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures. Schizophrenia 2025, 11: 85. PMID: 40480970, PMCID: PMC12144291, DOI: 10.1038/s41537-025-00622-0.Peer-Reviewed Original ResearchEvent-related oscillationsEEG power spectral densityClinical outcomesMarkers of illness progressionRisks of antipsychotic drugsAuditory steady state responsePredictor of clinical outcomeMismatch negativityVariable clinical outcomesControlled clinical trialsClinical high riskTest-retest reliabilitySecondary outcome measuresEEG-based measuresVisual P300Antipsychotic drugsPaired t-testEEG protocolsClinical trialsEffective medicationsInterim analysisHigh riskPersonalized treatmentTraditional frequency bandsCHR individualsElevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study.
Mack P, Redman M, Tukachinsky H, Kozono D, Minichiello K, Dragnev K, Tolba K, Neal J, Madison R, Waqar S, Aggarwal C, Hirsch F, Patel J, Herbst R, Chiang A, Reckamp K, Kelly K, Borghaei H, Gray J, Gandara D. Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study. Clinical Cancer Research 2025 PMID: 40465842, DOI: 10.1158/1078-0432.ccr-24-3658.Peer-Reviewed Original ResearchCirculating tumor DNAPositive percent agreementOverall survivalTumor fractionAdvanced NSCLCMutation detectionAdvanced non-small cell lung cancerAssociated with significantly worse overall survivalMaximum somatic allele frequencyNon-small cell lung cancerSignificantly worse overall survivalTF levelsCopy number gainCell lung cancerPaired tumor tissuesPatient overall survivalVariant allele frequencyMutational concordanceTumor aneuploidyAllele frequenciesFoundation MedicineTumor DNAClinical outcomesPlasma levelsLung cancerBreast Reconstruction in De Novo Metastatic Breast Cancer: A Systematic Review
Mattia A, Alomari M, Hyjazie T, Devisetti N, Shen Y, Haykal S. Breast Reconstruction in De Novo Metastatic Breast Cancer: A Systematic Review. Plastic & Reconstructive Surgery Global Open 2025, 13: e6810. PMID: 40469550, PMCID: PMC12133142, DOI: 10.1097/gox.0000000000006810.Peer-Reviewed Original ResearchMetastatic breast cancerDnMBC patientsBreast reconstructionClinical outcomesBreast cancerHuman epidermal growth factor receptor 2-positiveEpidermal growth factor receptor 2-positiveBreast cancer-specific survival ratesDe novo metastatic breast cancerCancer-specific survival ratesSurvival rateSystematic reviewImplant-based reconstructionMetastasize to boneInvasive ductal carcinomaProlonged survival rateLow disease burdenOligometastatic diseasePreferred Reporting ItemsPrimary tumorOverall survivalDuctal carcinomaEstrogen-positiveSurgical candidatesSurgical detailsReal-World Treatment Patterns, Clinical Outcomes, and Costs in Patients with Higher-Risk Myelodysplastic Syndromes Across France, Germany, and the United Kingdom
Drummond M, Finelli C, Kristo F, Kelkar S, Corman S, Raina R, Ashaye A, Dalal M, Haase D. Real-World Treatment Patterns, Clinical Outcomes, and Costs in Patients with Higher-Risk Myelodysplastic Syndromes Across France, Germany, and the United Kingdom. Journal Of Blood Medicine 2025, 16: 307-319. PMID: 40585910, PMCID: PMC12206415, DOI: 10.2147/jbm.s516558.Peer-Reviewed Original ResearchHigher-risk myelodysplastic syndromesReal-world treatment patternsTreatment patternsMyelodysplastic syndromeClinical outcomesProgression to acute myeloid leukemiaProgression-free survivalMedian patient ageMedian follow-upHigh-risk diseaseFirst-line treatmentKaplan-Meier methodAcute myeloid leukemiaHealthcare resource useFollow-up post-diagnosisIPSS-R.Partial remissionTransfusion-dependentOverall survivalPatient ageMyeloid leukemiaChart reviewClinical characteristicsAdjunctive therapyAdult patientsCirculating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study.
Yoo T, Heiling H, Santos K, Lipsyc-Sharf M, De Bruin E, Patel A, Kirkner G, Hughes M, Partridge A, Krop I, Howarth K, Winer E, Tolaney S, Tayob N, Lin N, Parsons H. Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study. Journal Of Clinical Oncology 2025, 43: 3055-3055. DOI: 10.1200/jco.2025.43.16_suppl.3055.Peer-Reviewed Original ResearchHR+/HER2- breast cancerNegative predictive valueAdjuvant settingBreast cancerFollow-upCtDNA testingDistant recurrenceClinical outcomesPlasma samplesHER2-negative breast cancerEarly-stage breast cancerRoutine surveillance imagingHormone receptor-positiveStage III diseaseYrs of follow-upMedian follow-upCirculating tumor DNALack of clinical recurrenceRisk of recurrenceFollow-up periodFollow-up visitMedian lead timeImpact clinical outcomesGuideline-concordant careCtDNA-negativeLong-term clinical outcomes with nivolumab/ipilimumab with or without Clostridium butyricum MIYAIRI588 in metastatic renal cell carcinoma (mRCC): A randomized phase Ib clinical trial.
Zugman M, Ebrahimi H, Meza L, Barragan-Carrillo R, Li X, Llamas-Quitiquit M, Hsu J, Zengin Z, Castro D, Mercier B, Jaime-Casas S, Chehrazi-Raffle A, Trent J, Lee P, Takahashi M, Dorff T, Caporaso G, Lee K, Pal S, Dizman N. Long-term clinical outcomes with nivolumab/ipilimumab with or without Clostridium butyricum MIYAIRI588 in metastatic renal cell carcinoma (mRCC): A randomized phase Ib clinical trial. Journal Of Clinical Oncology 2025, 43: 4550-4550. DOI: 10.1200/jco.2025.43.16_suppl.4550.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaProgression-free survivalClinical outcomesOverall survivalMedian progression-free survivalRandomized phase I trialTime of data cutoffPhase Ib clinical trialLong-term follow-up dataLong-term clinical outcomesObjective response rateDisease control ratePhase I trialRenal cell carcinomaSystemic immune responsesNewly diagnosed patientsFollow-up dataImproving clinical outcomesMedian OSSarcomatoid histologyCell histologyData cutoffIntermediate/high riskCell carcinomaI trialO-123 Ultrafast versus conventional blastocyst warming: equivalent developmental outcomes following the extended in vitro culture of 221 embryos beyond the implantation stages
Venturas M, Ardestani G, Zamora M, Azpiroz F, Pujol A, Mataró D, Rodriguez-Aranda A, Lledó B, Nodar F, Miguel-Escalada I, Sakkas D, Popovic M. O-123 Ultrafast versus conventional blastocyst warming: equivalent developmental outcomes following the extended in vitro culture of 221 embryos beyond the implantation stages. Human Reproduction 2025, 40: deaf097.123. DOI: 10.1093/humrep/deaf097.123.Peer-Reviewed Original ResearchPGT-AMaternal ageChromosomal statusClinical outcomesClinical studiesInner cell mass qualityExtended in vitro culturePost-warming survival rateWarming protocolDevelopmental potentialConventional warmingEmbryo developmental potentialPGT-A resultsPreimplantation genetic testingInvestigate clinical outcomesProspective clinical studyImplantation assayFisher's exact testFactors present in vivoDevelopmental outcomesEuploid blastocystsSurviving blastocystsTrophectoderm qualityEuploid embryosBlastocyst biopsyO-149 No effect of maternal age on embryo implantation and live birth rates after preimplantation genetic testing for aneuploidies: retrospective analysis of 11,855 single blastocyst transfers
Gayete-Mor B, Miguel-Escalada I, Kalafat E, Zamora M, Pujol A, Lledó B, Stoop D, Lorenzon A, Rodriguez-Aranda A, Sakkas D, Popovic M. O-149 No effect of maternal age on embryo implantation and live birth rates after preimplantation genetic testing for aneuploidies: retrospective analysis of 11,855 single blastocyst transfers. Human Reproduction 2025, 40: deaf097.149. DOI: 10.1093/humrep/deaf097.149.Peer-Reviewed Original ResearchEuploid embryo transferAge-related fertility declineAdvanced maternal ageLive birth ratePreimplantation genetic testingEmbryo qualityMaternal ageLive birthsEuploid embryosFertility declineEmbryo transferClinical outcomesClinical pregnancyEffect of maternal agePGT-AAssociated with poor embryo qualityBirth rateOlder patientsGenetic testingReproductive outcomesEuploid blastocyst transferGood-quality blastocystsReduced oocyte yieldPoor embryo qualityPoor-quality embryosImpact of a novel oral medication delivery device on patient engagement and discontinuation in individuals receiving oral oncolytic medications.
Taylor M, Fuhr K, Heiland K, Huntington S, Lustberg M, Schellhorn S. Impact of a novel oral medication delivery device on patient engagement and discontinuation in individuals receiving oral oncolytic medications. Journal Of Clinical Oncology 2025, 43: 11063-11063. DOI: 10.1200/jco.2025.43.16_suppl.11063.Peer-Reviewed Original ResearchPatient-reported outcomesHistorical control groupDose reductionControl groupAdverse event-related discontinuationsEvaluate dose reductionMedication delivery devicesHistorical control cohortTime of dosingDelivery devicesRibociclib groupEarly toxicityDiscontinuation ratesMedian ageMedication toleranceAcute care utilizationClinical outcomesHistorical controlsOral medicationsRibociclibControl cohortTreatment adjustmentMedication discontinuationAcalabrutinibCohort of individualsGut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial.
Saliby R, Machaalani M, Zhong C, Alves Costa Silva C, Labaki C, Saad E, Steiner C, Yekeduz E, Eid M, Daoud Khatoun W, Sun M, Cai T, Braun D, Xu W, Derosa L, Lee G, Xie W, Albiges L, Zitvogel L, Choueiri T. Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial. Journal Of Clinical Oncology 2025, 43: 4512-4512. DOI: 10.1200/jco.2025.43.16_suppl.4512.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaProgression-free survivalRestricted cubic splinesSMAdCAM-1Immune checkpoint inhibitorsOverall survivalCox regression modelsGut dysbiosisAssociated with progression-free survivalAnti-cancer immune responseOptimal cut-off valueICI-based therapyIMDC risk groupsRenal cell carcinomaCut-off valueRestricted cubic spline plotsLog-rank statisticsJAVELIN RenalCheckpoint inhibitorsOS ratesOS outcomesCell carcinomaPrognostic valueLuminex assayClinical outcomesUnveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists [Podcast]
Zeidan A, Loghavi S. Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists [Podcast]. Blood And Lymphatic Cancer Targets And Therapy 2025, 15: 39-45. PMID: 40575712, PMCID: PMC12198350, DOI: 10.2147/blctt.s543541.Peer-Reviewed Original ResearchNext-generation sequencingAcute myeloid leukemiaSingle-gene PCRMolecular diagnosticsSingle-geneSanger sequencingGene fusionsMolecular testingRNA analysisMD Anderson Cancer CenterCapillary electrophoresisImproving clinical outcomesAML managementMyeloid leukemiaTargeted therapyClinical outcomesSequencePCRCancer CenterMolecular profilingPersonalized therapyAssay selectionClinical importanceTesting modalitiesSangerPrediction of Lymph Node Metastasis in Non–Small Cell Lung Carcinoma Using Primary Tumor Somatic Mutation Data
Lee V, Moore N, Doyle J, Hicks D, Oh P, Bodofsky S, Hossain S, Patel A, Aneja S, Homer R, Park H. Prediction of Lymph Node Metastasis in Non–Small Cell Lung Carcinoma Using Primary Tumor Somatic Mutation Data. JCO Clinical Cancer Informatics 2025, 9: e2400303. PMID: 40446175, DOI: 10.1200/cci-24-00303.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerLymph node metastasisArea under the receiver operating characteristic curveNode metastasisTreatment strategiesNon-small cell lung carcinomaPrediction of lymph node metastasisSurvival analysisSNP dataLymph node metastasis statusAssociated with lymph node metastasisCell lung carcinomaCell lung cancerLymph node metastasis predictionReceiver operating characteristic curveDiagnostic methodsPersonalized treatment strategiesSingle-nucleotide polymorphism (SNPChi-square testMedian AUCLung carcinomaClinical outcomesNon-smallRisk stratificationLogistic regression modelsClinical outcomes following brachytherapy for endometrial cancer patients with narrow vaginal anatomy
Adefres B, Tien C, Gueble S, Damast S. Clinical outcomes following brachytherapy for endometrial cancer patients with narrow vaginal anatomy. Brachytherapy 2025 PMID: 40447531, DOI: 10.1016/j.brachy.2025.04.002.Peer-Reviewed Original ResearchHigh-dose-rateVaginal brachytherapyVaginal recurrenceEndometrial cancerClinical outcomesStage I-II diseaseClinical outcome of EC patientsHigher surface doseIn-field recurrenceOutcome of EC patientsExcellent local controlIRB-approved databaseKaplan-Meier analysisEndometrial cancer patientsVaginal cylinderUrinary toxicityVaginal stenosisCTCAE v4.0Dose heterogeneityVaginal scarringVaginal anatomyMedian ageRecurrence rateSurface dosePatient demographicsComprehensive characterization of interleukin-enhanced factor 2 (ILF2) in triple-negative breast cancer (TNBC).
Bustos M, Deshmukh S, Samec T, Wu S, Xiu J, Advani P, Jayachandran P, Mahtani R, Graff S, Lustberg M, Grumley J, Sledge G, Hoon D. Comprehensive characterization of interleukin-enhanced factor 2 (ILF2) in triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2025, 43: 1114-1114. DOI: 10.1200/jco.2025.43.16_suppl.1114.Peer-Reviewed Original ResearchTriple-negative breast cancerOverall survivalTumor microenvironmentBreast cancerManagement of triple-negative breast cancerInfiltration of NK cellsImmune suppressive tumor microenvironmentReal-world overall survivalSuppressive tumor microenvironmentPercentage of younger patientsDrug efflux genesImmune cell fractionsStem cell genesMann-Whitney U testKaplan-Meier estimatesL groupImmune checkpointsShorter OSNK cellsTNBC patientsTherapy resistanceTherapeutic optionsYounger patientsClinical outcomesFisher's exactRepolarisation abnormalities and outcomes among patients with cardiac arrest
Schenck C, Banna S, Kim N, Nguyen C, Gilmore E, Greer D, Beekman R, Miller P. Repolarisation abnormalities and outcomes among patients with cardiac arrest. European Heart Journal Acute Cardiovascular Care 2025, zuaf077. PMID: 40424593, DOI: 10.1093/ehjacc/zuaf077.Peer-Reviewed Original ResearchReturn of spontaneous circulationIn-hospital mortalityAssociated with in-hospital mortalityQTc prolongationCardiac arrestInterval prolongationShockable rhythmNeurological outcomeClinical outcomesAssociated with increased in-hospital mortalityAssociated with adverse clinical outcomesTpTe intervalT-peak to T-endSusceptibility to ventricular arrhythmiasQTc interval prolongationIn-hospital cardiac arrestAdverse clinical outcomesT-end (TpTeOut-of-hospitalT-endSpontaneous circulationVentricular arrhythmiasVentricular repolarizationQTcRepolarisation abnormalities
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply